Premium
The Use of Fidaxomicin for Treatment of Relapsed Clostridium difficile Infections in Patients with Cancer
Author(s) -
EsmailyFard Amin,
Tverdek Frank P.,
Crowther David M.,
Ghantoji Shashank S.,
Adachi Javier A.,
Chemaly Roy F.
Publication year - 2014
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1479
Subject(s) - medicine , concomitant , clostridium difficile , fidaxomicin , adverse effect , cancer , metronidazole , retrospective cohort study , surgery , antibiotics , vancomycin , genetics , bacteria , microbiology and biotechnology , biology , staphylococcus aureus
Objectives To report our experience with the use of fidaxomicin ( FDX ), an oral macrocyclic antibiotic, in cancer patients with Clostridium difficile infection ( CDI ). Methods A single‐center retrospective case series was conducted at The University of Texas MD Anderson Cancer Center. Patients with CDI treated with FDX from May 2011 to January 2013 were identified via the pharmacy database. Clinical response and recurrence after FDX initiation were evaluated. Results Twenty‐two patients were included, most of whom were male (55%) with a mean age of 58 years (range: 20–83 yrs). The most common underlying malignancies were nine patients with lymphoma (41%), seven with leukemia (32%), and six with solid tumors (27%). Indications for FDX included recurrent CDI in 16 patients (72%) and failure of both metronidazole and oral vancomycin in 6 patients (28%). Nineteen patients (86%) were on concomitant antimicrobials during CDI treatment. Clinical response to FDX was 91%, and overall sustained clinical response was 82%. FDX was well tolerated with no major adverse events that were FDX related or discontinuations due to drug‐related adverse events. Conclusion In cancer patients, FDX is effective treatment for the first episode of CDI after failure of standard therapies and treatment of recurrent CDI . This was interesting given the large number of high‐risk patients who continued to receive concomitant antimicrobial therapy, which is common in this immunocompromised patient population.